Swedish   English

Disclaimer

The information contained in this section of this website contains information relating to an offer to
existing shareholders and the public in Sweden to subscribe for class B shares in Biovica International
AB (publ) (the “Company”) in connection with the Company’s rights issue. This information may not
be accessed by residents of certain countries based on applicable securities law regulations.

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WHOLLY OR PARTLY, IN THE
UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS), ANY
STATE OF THE UNITED STATES INCLUDING THE DISTRICT OF COLUMBIA, AUSTRALIA,
CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SWITZERLAND, SOUTH
AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE
PROHIBITED BY APPLICABLE LAW.

This website and the information contained herein is not intended for, and may not be accessed by, or
distributed or disseminated to, persons resident or physically present in the United States of America
(including its territories and possessions), any state of the United States including the District of
Columbia (the “United States”), Australia, Canada, Hong Kong, Japan, New Zealand, Singapore,
Switzerland, South Africa, South Korea and do not constitute an offer to sell or the solicitation of an
offer to purchase or acquire, any shares in the Company in any of the above mentioned jurisdictions
or in any other jurisdiction in which such offer or solicitation would be unlawful prior to registration
or qualification under the securities laws of such jurisdiction. The shares in the Company referred to
on this website have not been, and will not be, registered under the Securities Act of 1933, as
amended (the “Securities Act”), and may not be offered or sold in the United States absent
registration or an exemption from registration under the Securities Act.

All persons residing outside of the above mentioned jurisdictions who wish to access the documents
contained on this website should first ensure that they are not subject to local laws or regulations that
prohibit or restrict their right to access this website, or require registration or approval for any
acquisition of securities by them. The Company assumes no responsibility if there is a violation of
applicable law and regulations by any person.

If you are not permitted to view materials on this website or are in any doubt as to whether you are
permitted to view these materials, please exit this website.
Access to electronic versions of these materials is being made available on this website by the
Company in good faith and for information purposes only.


By clicking “Confirm” you confirm and certify that:

  • You are not a resident of or physically present in any of the above jurisdictions or any other
    restricted jurisdiction and are not a U.S. person (as defined in Regulation S under the
    Securities Act); and
  • you are either:
    • a resident of, or physically present in, Sweden;
    • if resident or physically present in a Member State of the European Economic Area
      other than Sweden, a qualified investor as defined in Regulation (EU) 2017/1129 of
      the European parliament and of the council; or
    • otherwise authorized to access this information pursuant to applicable laws or
      regulations.

Confirm

Don’t confirm

>4,500

Numbers of patients in studies

28

Publications

19

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No